SciBase announced this morning that it has submitted a 510(k) premarket notification to the FDA seeking to expand the indication for Nevisense to include non-melanoma skin cancer (keratinocyte skin cancer). We view this as a meaningful milestone that broadens the platform's addressable market and clinical relevance in the company's key growth region.
LÄS MER
